School of Medicine


Showing 191-200 of 547 Results

  • Sumit Shah

    Sumit Shah

    Clinical Associate Professor, Medicine - Oncology
    Clinical Associate Professor (By courtesy), Urology

    BioDr. Sumit Shah is a medical oncologist specializing in the management of advanced urologic malignancies, including prostate, kidney, bladder, and testicular cancers. He serves as an investigator on numerous clinical trials, with a particular focus on novel immunotherapy agents. His academic interests also encompass digital health technologies and innovative healthcare delivery models, both domestically and internationally.

    Dr. Shah graduated with distinction in biomedical engineering from Duke University, earned his MD from Stanford University, and completed a Master of Public Health at Harvard University. He trained in internal medicine at the University of California, San Francisco (UCSF), where he remained on faculty for one year before returning to Stanford for his fellowship in medical oncology. He now holds a faculty position in the Department of Medicine (Oncology) at Stanford.

    In addition to his clinical and research roles, Dr. Shah serves as Medical Director of Digital Health Integration and Director of Infusion Services at Stanford Hospital. He is also Assistant Dean of Academic Advising in the Stanford School of Medicine.

  • Jay Shah

    Jay Shah

    Associate Professor of Urology

    BioDr. Jay Shah, MD currently serves as Chief of the Medical Staff for Stanford Health Care. He is a cancer surgeon and associate professor of Urology at the Stanford University School of Medicine. His clinical focus is on bladder cancer, and he is well known for his expertise in robotic surgery. His academic interests center on optimizing outcomes after bladder removal surgery. He is very active in leadership development, team building, and quality improvement work and he lectures nationally and internationally on these topics. He is also certified by the International Coaching Federation as an executive coach.

    Dr. Shah graduated from Harvard College, and he completed medical school and urology residency training at Columbia University. During his time at Columbia, Dr. Shah was elected to the Alpha Omega Alpha Medical Honor Society; he was named Physician of the Year by the nursing staff; and he was recognized by the medical students with the Gold Foundation Excellence in Teaching Award. After residency, he completed a three-year fellowship in Urologic Oncology at MD Anderson Cancer Center and then joined the faculty there. During his time at MD Anderson, Dr. Shah launched the bladder cancer robotics program, developed an enhanced recovery program for patients undergoing bladder removal surgery, became double board-certified in Urology and Medical Quality, and was chosen to lead the MDACC Genitourinary Center as Center Medical Director.
    In his free time, Dr. Shah enjoys reading, cooking, and exploring the beaches of Northern California with his family and three dogs.

    In his free time, Dr. Shah enjoys reading, cooking, surfing, hiking and exploring the beaches of Northern California in his Jeep Wrangler with his family and 2 dogs.

  • Shagufta Shaheen

    Shagufta Shaheen

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.

  • Mohammad Shahrokh Esfahani

    Mohammad Shahrokh Esfahani

    Assistant Professor of Radiation Oncology (Radiation and Cancer Biology)

    BioI lead a computational oncology laboratory that develops machine learning and statistical methods for high-dimensional genomics, with particular expertise in Bayesian and uncertainty-aware modeling to integrate prior biological knowledge with large-scale datasets.

    Our research centers on liquid biopsy analytics—especially cell-free DNA (cfDNA)—to noninvasively quantify genetic and epigenetic states relevant to cancer detection, monitoring, and tumor evolution. We developed EPIC-seq, a fragmentomics-based method that uses cfDNA fragmentation patterns to infer regulatory activity and gene expression programs, providing a scalable framework for epigenetic profiling from blood.

    A core methodological focus of the lab is enabling reliable inference in extremely low signal-to-noise settings that are typical of cfDNA and early-stage disease. We build robust, interpretable models and benchmarking frameworks that support clinical translation, with the long-term aim of democratizing access to sensitive, minimally invasive cancer diagnostics.

  • Mehrdad Shamloo

    Mehrdad Shamloo

    Professor (Research) of Neurosurgery and, by courtesy, of Neurology and Neurological Sciences

    Current Research and Scholarly InterestsThe ultimate goal of the Shamloo laboratory is to rapidly advance our understanding of brain function at the molecular, cellular, circuit and behavioral levels, and to elucidate the pathological process underlying malfunction of the nervous system following injury and neurologic disorders such as stroke, Alzheimer's disease, Parkinson’s disease, and autism. We have been focusing on the noradrenergic system and approaches leading to restoration of brain adrenergic signaling in these disorders.